Divalproex Sodium
Product Images NDC 53808-0356

6 FDA label images from State Of Florida Doh Central Pharmacy · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 53808-0356). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structural Formula (3cd35eb6 Df66 4848 86dd F1fa47731057 01)

Structural Formula (3cd35eb6 Df66 4848 86dd F1fa47731057 01)
Chemical structure of divalproex sodium showing a polymeric complex consisting of valproic acid and sodium valproate units linked in an overlapping repeating pattern.*
FDA Label Image

Divalproex Figure 1 (3cd35eb6 Df66 4848 86dd F1fa47731057 02)

Divalproex Figure 1 (3cd35eb6 Df66 4848 86dd F1fa47731057 02)
Bar chart comparing percentage outcomes for placebo (PBO) and Divalproex sodium delayed-release tablets (DVPX) in two studies: Study 1 (YMRS) and Study 2 (MRS). The chart shows higher percentages for DVPX (60% and 58%) compared to placebo (26% and 29%), with a statistical significance mark.*
FDA Label Image

Divalproex Figure 2 (3cd35eb6 Df66 4848 86dd F1fa47731057 03)

Divalproex Figure 2 (3cd35eb6 Df66 4848 86dd F1fa47731057 03)
A bar chart comparing two studies showing the effects of Placebo versus Divalproex Sodium Delayed Release. The y-axis measures an unspecified variable from 0 to 6, with Placebo bars higher than Divalproex Sodium Delayed Release in both Study 1 and Study 2. Footnotes indicate dosing details for the delayed-release tablets in each study.*
FDA Label Image

Divalproex Figure 3 (3cd35eb6 Df66 4848 86dd F1fa47731057 04)

Divalproex Figure 3 (3cd35eb6 Df66 4848 86dd F1fa47731057 04)
A line graph comparing the percentage reduction in CPS rate between Divalproex Sodium Delayed-Release and placebo over a percentage of patients. The y-axis represents the percent reduction in CPS rate, with labels indicating improvement and worsening, while the x-axis shows the percentage of patients.*
FDA Label Image

Divalproex Figure 4 (3cd35eb6 Df66 4848 86dd F1fa47731057 05)

Divalproex Figure 4 (3cd35eb6 Df66 4848 86dd F1fa47731057 05)
A chart showing the percentage reduction in CPS (complex partial seizures) rate versus the percentage of patients for high dose and low dose Divalproex Sodium Delayed Release. The vertical axis indicates improvement or worsening, while the horizontal axis shows the percentage of patients. Two curves represent high dose (solid line) and low dose (dashed line) effects.*
FDA Label Image

Divalproex Sodium Delayed-release Tablets 250 mg (Divalproex 250mg(mylan))

Divalproex Sodium Delayed-release Tablets 250 mg (Divalproex 250mg(mylan))
A white pharmacy label for Divalproex Sodium DR 250 mg tablets, prescription only, with a quantity of 30 tablets. The label includes the lot number 3013757, expiration date August 2011, and indicates packaging by DOH Central Pharmacy in Tallahassee, Florida. A UPC barcode is also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.